Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Thyroid Diseases HELP
Based on 37,536 articles published since 2007
||||

These are the 37536 published articles about Thyroid Diseases that originated from Worldwide during 2007-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. 2018

Jarząb, Barbara / Dedecjus, Marek / Słowińska-Klencka, Dorota / Lewiński, Andrzej / Adamczewski, Zbigniew / Anielski, Ryszard / Bagłaj, Maciej / Bałdys-Waligórska, Agata / Barczyński, Marcin / Bednarczuk, Tomasz / Bossowski, Artur / Buziak-Bereza, Monika / Chmielik, Ewa / Cichocki, Andrzej / Czarniecka, Agnieszka / Czepczyński, Rafał / Dzięcioł, Janusz / Gawlik, Tomasz / Handkiewicz-Junak, Daria / Hasse-Lazar, Kornelia / Hubalewska-Dydejczyk, Alicja / Jażdżewski, Krystian / Jurecka-Lubieniecka, Beata / Kalemba, Michał / Kamiński, Grzegorz / Karbownik-Lewińska, Małgorzata / Klencki, Mariusz / Kos-Kudła, Beata / Kotecka-Blicharz, Agnieszka / Kowalska, Aldona / Krajewska, Jolanta / Kropińska, Aleksandra / Kukulska, Aleksandra / Kulik, Emilia / Kułakowski, Andrzej / Kuzdak, Krzysztof / Lange, Dariusz / Ledwon, Aleksandra / Lewandowska-Jabłońska, Elżbieta / Łącka, Katarzyna / Michalik, Barbara / Nasierowska-Guttmejer, Anna / Nauman, Janusz / Niedziela, Marek / Małecka-Tendera, Ewa / Oczko-Wojciechowska, Małgorzata / Olczyk, Tomasz / Paliczka-Cieślik, Ewa / Pomorski, Lech / Puch, Zbigniew / Roskosz, Józef / Ruchała, Marek / Rusinek, Dagmara / Sporny, Stanisław / Stanek-Widera, Agata / Stojcev, Zoran / Syguła, Aleksandra / Syrenicz, Anhelli / Szpak-Ulczok, Sylwia / Tomkalski, Tomasz / Wygoda, Zbigniew / Włoch, Jan / Zembala-Nożyńska, Ewa. ·Nuclear Medicine and Endocrine Oncology Department; M.Sklodowska-Curie Memorial Institute - Cancer Center, Gliwice Branch, Wybrzeze AK 15, 44-100 Gliwice, Poland; Zakład Medycyny Nuklearnej i Endokrynologii Onkologicznej, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach, Wybrzeże AK 15, 44-100 Gliwice, Poland. barbara.jarzab@io.gliwice. ·Endokrynol Pol · Pubmed #29442352.

ABSTRACT: Significant advances have been made in thyroid can-cer research in recent years, therefore relevant clinical guidelines need to be updated. The current Polish guidelines "Diagnostics and Treatment of Thyroid Carcinoma" have been formulated at the "Thyroid Cancer and Other Malignancies of Endocrine Glands" conference held in Wisła in November 2015 [1].

2 Guideline [Study and management of thyroid nodes by non specialist physicians: SOCHED consensus]. 2017

Tala, Hernán / Díaz, René E / Domínguez Ruiz-Tagle, José Miguel / Sapunar Zenteno, Jorge / Pineda, Pedro / Arroyo Albala, Patricia / Barberán, Marcela / Cabané, Patricio / Cruz Olivos, Francisco / Gac E, Patricio / Glasinovic Pizarro, Andrea / González, Hernán E / Grob, Francisca / Hidalgo Valle, Maria Soledad / Jaimovich, Rodrigo / Lanas, Alejandra / Liberman, Claudio / Lobo Guiñez, Maite / Madrid, Arturo. ·Unidad de Endocrinología, Departamento de Medicina Interna, Clínica Alemana de Santiago, Santiago, Chile. · Sección Endocrinología, Hospital del Salvador, Santiago, Chile. · Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. · Departamento Medicina Interna, Centro EPICYN, Facultad de Medicina, Universidad de la Frontera, Temuco, Chile. · Hospital Clínico, Universidad de Chile, Santiago, Chile. · Clínica Universidad de los Andes, Santiago, Chile. · Departamento de Radiología, Pontificia Universidad Católica de Chile, Santiago, Chile. · Clínica Santa María, Santiago, Chile. · Departamento de Cirugía Oncológica, Pontificia Universidad Católica de Chile, Santiago, Chile. · División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. · Hospital San Borja-Arriarán, Santiago, Chile. · Medicina Nuclear, Clínica Las Condes, Santiago, Chile. · Centro de Diagnóstico Plaza Italia, Santiago, Chile. · Unidad de Cirugía de Cabeza y Cuello, Departamento de Cirugía, Clínica Alemana de Santiago, Santiago, Chile. ·Rev Med Chil · Pubmed #29189861.

ABSTRACT: The thyroid nodule is a frequent cause of primary care consultation. The prevalence of a palpable thyroid nodule is approximately 4-7%, increasing up to 67% by the incidental detection of nodules on ultrasound. The vast majority are benign and asymptomatic, staying stable over time. The clinical importance of studying a thyroid nodule is to exclude thyroid cancer, which occurs in 5 to 10% of the nodules. The Board of SOCHED (Chilean Society of Endocrinology and Diabetes) asked the Thyroid Study Group to develop a consensus regarding the diagnostic management of the thyroid nodule in Chile, aimed at non-specialist physicians and adapted to the national reality. To this end, a multidisciplinary group of 31 experts was established among university academics, active researchers with publications on the subject and prominent members of scientific societies of endocrinology, head and neck surgery, pathology and radiology. A total of 14 questions were developed with key aspects for the diagnosis and subsequent referral of patients with thyroid nodules, which were addressed by the participants. In those areas where the evidence was insufficient or the national reality had to be considered, the consensus opinion of the experts was used through the Delphi methodology. The consensus was approved by the SOCHED board for publication.

3 Guideline The 2017 Bethesda System for Reporting Thyroid Cytopathology. 2017

Cibas, Edmund S / Ali, Syed Z. ·1 Departments of Pathology, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts. · 2 Department of Pathology, The Johns Hopkins Medical Institutions , Baltimore, Maryland. ·Thyroid · Pubmed #29091573.

ABSTRACT: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. There is a choice of two different names for some of the categories. A laboratory should choose the one it prefers and use it exclusively for that category. Synonymous terms (e.g., AUS and FLUS) should not be used to denote two distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the "benign" category to virtually 100% for the "malignant" category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.

4 Guideline Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. 2017

Anonymous5790906 / Bibbins-Domingo, Kirsten / Grossman, David C / Curry, Susan J / Barry, Michael J / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Kemper, Alex R / Krist, Alex H / Kurth, Ann E / Landefeld, C Seth / Mangione, Carol M / Phipps, Maureen G / Silverstein, Michael / Simon, Melissa A / Siu, Albert L / Tseng, Chien-Wen. ·University of California, San Francisco. · Kaiser Permanente Washington Health Research Institute, Seattle. · University of Iowa, Iowa City. · Harvard Medical School, Boston, Massachusetts. · Columbia University, New York, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Duke University, Durham, North Carolina. · Fairfax Family Practice Residency, Fairfax, Virginia10Virginia Commonwealth University, Richmond. · Yale University, New Haven, Connecticut. · University of Alabama at Birmingham, Birmingham. · University of California, Los Angeles. · Brown University, Providence, Rhode Island. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · Mount Sinai Hospital, New York, New York18James J. Peters Veterans Affairs Medical Center, Bronx, New York. · Pacific Health Research and Education Institute, Honolulu, Hawaii20University of Hawaii, Honolulu. ·JAMA · Pubmed #28492905.

ABSTRACT: Importance: The incidence of thyroid cancer detection has increased by 4.5% per year over the last 10 years, faster than for any other cancer, but without a corresponding change in the mortality rate. In 2013, the incidence rate of thyroid cancer in the United States was 15.3 cases per 100 000 persons. Most cases of thyroid cancer have a good prognosis; the 5-year survival rate for thyroid cancer overall is 98.1%. Objective: To update the US Preventive Services Task Force (USPSTF) recommendation on screening for thyroid cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic accuracy of screening (including neck palpation and ultrasound), and the benefits and harms of treatment of screen-detected thyroid cancer. Findings: The USPSTF found inadequate direct evidence on the benefits of screening but determined that the magnitude of the overall benefits of screening and treatment can be bounded as no greater than small, given the relative rarity of thyroid cancer, the apparent lack of difference in outcomes between patients who are treated vs monitored (for the most common tumor types), and observational evidence showing no change in mortality over time after introduction of a mass screening program. The USPSTF found inadequate direct evidence on the harms of screening but determined that the overall magnitude of the harms of screening and treatment can be bounded as at least moderate, given adequate evidence of harms of treatment and indirect evidence that overdiagnosis and overtreatment are likely to be substantial with population-based screening. The USPSTF therefore determined that the net benefit of screening for thyroid cancer is negative. Conclusions and Recommendation: The USPSTF recommends against screening for thyroid cancer in asymptomatic adults. (D recommendation).

5 Guideline American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. 2017

Haugen, Bryan R / Sawka, Anna M / Alexander, Erik K / Bible, Keith C / Caturegli, Patrizio / Doherty, Gerard M / Mandel, Susan J / Morris, John C / Nassar, Aziza / Pacini, Furio / Schlumberger, Martin / Schuff, Kathryn / Sherman, Steven I / Somerset, Hilary / Sosa, Julie Ann / Steward, David L / Wartofsky, Leonard / Williams, Michelle D. ·1 University of Colorado School of Medicine , Aurora, Colorado. · 2 University Health Network, University of Toronto , Toronto, Canada . · 3 Brigham and Women's Hospital , Harvard Medical School, Boston, Massachusetts. · 4 The Mayo Clinic , Rochester, Minnesota. · 5 Johns Hopkins University School of Medicine , Baltimore, Maryland. · 6 Boston Medical Center , Boston, Massachusetts. · 7 Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania. · 8 The Mayo Clinic , Jacksonville, Florida. · 9 The University of Siena , Siena, Italy . · 10 Institute Gustave Roussy and University Paris Sud , Villejuif, France . · 11 Oregon Health and Science University , Portland, Oregon. · 12 University of Texas M.D. Anderson Cancer Center , Houston, Texas. · 13 Duke University School of Medicine , Durham, North Carolina. · 14 University of Cincinnati Medical Center , Cincinnati, Ohio. · 15 MedStar Washington Hospital Center , Washington, DC. ·Thyroid · Pubmed #28114862.

ABSTRACT: American Thyroid Association (ATA) leadership asked the ATA Thyroid Nodules and Differentiated Thyroid Cancer Guidelines Task Force to review, comment on, and make recommendations related to the suggested new classification of encapsulated follicular variant papillary thyroid carcinoma (eFVPTC) without capsular or vascular invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The task force consists of members from the 2015 guidelines task force with the recusal of three members who were authors on the paper under review. Four pathologists and one endocrinologist were added for this specific review. The manuscript proposing the new classification and related literature were assessed. It is recommended that the histopathologic nomenclature for eFVPTC without invasion be reclassified as a NIFTP, given the excellent prognosis of this neoplastic variant. This is a weak recommendation based on moderate-quality evidence. It is also noted that prospective studies are needed to validate the observed patient outcomes (and test performance in predicting thyroid cancer outcomes), as well as implications on patients' psychosocial health and economics.

6 Guideline Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology. 2017

Na, Dong Gyu / Baek, Jung Hwan / Jung, So Lyung / Kim, Ji-Hoon / Sung, Jin Yong / Kim, Kyu Sun / Lee, Jeong Hyun / Shin, Jung Hee / Choi, Yoon Jung / Ha, Eun Ju / Lim, Hyun Kyung / Kim, Soo Jin / Hahn, Soo Yeon / Lee, Kwang Hwi / Choi, Young Jun / Youn, Inyoung / Kim, Young Joong / Ahn, Hye Shin / Ryu, Ji Hwa / Baek, Seon Mi / Sim, Jung Suk / Jung, Chan Kwon / Lee, Joon Hyung / Anonymous2080981. ·Department of Radiology, Human Medical Imaging and Intervention Center, Seoul 06524, Korea. · Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea. · Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea. · Department of Radiology, Seoul National University College of Medicine, Seoul 03080, Korea. · Department of Radiology and Thyroid Center, Daerim St. Mary's Hospital, Seoul 07442, Korea. · Department of Radiology and Thyroid Center, Daerim St. Mary's Hospital, Seoul 07442, Korea.; Department of Radiology, Smarton Hospital, Bucheon 14534, Korea. · Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea. · Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul 03181, Korea. · Department of Radiology, Ajou University School of Medicine, Suwon 16499, Korea. · Department of Radiology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul 04401, Korea. · Department of Radiology, Human Medical Imaging and Intervention Center, Seoul 06524, Korea.; Department of Radiology, New Korea Hospital, Kimpo 10086, Korea. · Department of Radiology, Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Korea. · Department of Radiology, Konyang University Hospital, Konyang University College of Medicine, Daejeon 35365, Korea. · Department of Radiology and Thyroid Center, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul 06973, Korea. · Department of Radiology, Sharing and Happiness Hospital, Busan 48101, Korea. · Department of Radiology, Withsim Clinic, Seongnam 13590, Korea. · Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea. · Department of Radiology, Dong-A University Medical Center, Busan 49201, Korea. ·Korean J Radiol · Pubmed #28096731.

ABSTRACT: Core needle biopsy (CNB) has been suggested as a complementary diagnostic method to fine-needle aspiration in patients with thyroid nodules. Many recent CNB studies have suggested a more advanced role for CNB, but there are still no guidelines on its use. Therefore, the Task Force Committee of the Korean Society of Thyroid Radiology has developed the present consensus statement and recommendations for the role of CNB in the diagnosis of thyroid nodules. These recommendations are based on evidence from the current literature and expert consensus.

7 Guideline Diagnostics and treatment of differentiated thyroid carcinoma in children - Guidelines of Polish National Societies. 2016

Niedziela, Marek / Handkiewicz-Junak, Daria / Małecka-Tendera, Ewa / Czarniecka, Agnieszka / Dedecjus, Marek / Lange, Dariusz / Kucharska, Anna / Gawlik, Aneta / Pomorski, Lech / Włoch, Jan / Bagłaj, Maciej / Słowińska-Klencka, Dorota / Sporny, Stanisław / Kurzawa, Paweł / Kropińska, Aleksandra / Krajewska, Jolanta / Czepczyński, Rafał / Ruchała, Marek / Lewiński, Andrzej / Jarząb, Barbara. ·Department of Paediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Poznan, Poland. mniedzie@ump.edu.pl. ·Endokrynol Pol · Pubmed #28042655.

ABSTRACT: -- No abstract --

8 Guideline Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. 2016

Mitchell, A L / Gandhi, A / Scott-Coombes, D / Perros, P. ·The Newcastle upon Tyne Hospitals NHS Foundation Trust,Newcastle upon Tyne,UK. · Department of Breast and Endocrine Surgery,University Hospital of South Manchester,Manchester,UK. · University Hospital of Wales,Cardiff,UK. ·J Laryngol Otol · Pubmed #27841128.

ABSTRACT: This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the management of thyroid cancer in adults and is based on the 2014 British Thyroid Association guidelines. Recommendations • Ultrasound scanning (USS) of the nodule or goitre is a crucial investigation in guiding the need for fine needle aspiration cytology (FNAC). (R) • FNAC should be considered for all nodules with suspicious ultrasound features (U3-U5). If a nodule is smaller than 10 mm in diameter, USS guided FNAC is not recommended unless clinically suspicious lymph nodes on USS are also present. (R) • Cytological analysis and categorisation should be reported according to the current British Thyroid Association Guidance. (R) • Ultrasound scanning assessment of cervical nodes should be done in FNAC-proven cancer. (R) • Magnetic resonance imaging (MRI) or computed tomography (CT) should be done in suspected cases of retrosternal extension, fixed tumours (local invasion with or without vocal cord paralysis) or when haemoptysis is reported. When CT with contrast is used pre-operatively, there should be a two-month delay between the use of iodinated contrast media and subsequent radioactive iodine (I131) therapy. (R) • Fluoro-deoxy-glucose positron emission tomography imaging is not recommended for routine evaluation. (G) • In patients with thyroid cancer, assessment of extrathyroidal extension and lymph node disease in the central and lateral neck compartments should be undertaken pre-operatively by USS and cross-sectional imaging (CT or MRI) if indicated. (R) • For patients with Thy 3f or Thy 4 FNAC a diagnostic hemithyroidectomy is recommended. (R) • Total thyroidectomy is recommended for patients with tumours greater than 4 cm in diameter or tumours of any size in association with any of the following characteristics: multifocal disease, bilateral disease, extrathyroidal spread (pT3 and pT4a), familial disease and those with clinically or radiologically involved nodes and/or distant metastases. (R) • Subtotal thyroidectomy should not be used in the management of thyroid cancer. (G) • Central compartment neck dissection is not routinely recommended for patients with papillary thyroid cancer without clinical or radiological evidence of lymph node involvement, provided they meet all of the following criteria: classical type papillary thyroid cancer, patient less than 45 years old, unifocal tumour, less than 4 cm, no extrathyroidal extension on ultrasound. (R) • Patients with metastases in the lateral compartment should undergo therapeutic lateral and central compartment neck dissection. (R) • Patients with follicular cancer with greater than 4 cm tumours should be treated with total thyroidectomy. (R) • I131 ablation should be carried out only in centres with appropriate facilities. (R) • Serum thyroglobulin (Tg) should be checked in all post-operative patients with differentiated thyroid cancer (DTC), but not sooner than six weeks after surgery. (R) • Patients who have undergone total or near total thyroidectomy should be started on levothyroxine 2 µg per kg or liothyronine 20 mcg tds after surgery. (R) • The majority of patients with a tumour more than 1 cm in diameter, who have undergone total or near-total thyroidectomy, should have I131 ablation. (R) • A post-ablation scan should be performed 3-10 days after I131 ablation. (R) • Post-therapy dynamic risk stratification at 9-12 months is used to guide further management. (G) • Potentially resectable recurrent or persistent disease should be managed with surgery whenever possible. (R) • Distant metastases and sites not amenable to surgery which are iodine avid should be treated with I131 therapy. (R) • Long-term follow-up for patients with differentiated thyroid cancer (DTC) is recommended. (G) • Follow-up should be based on clinical examination, serum Tg and thyroid-stimulating hormone assessments. (R) • Patients with suspected medullary thyroid cancer (MTC) should be investigated with calcitonin and carcino-embryonic antigen levels (CEA), 24 hour catecholamine and nor metanephrine urine estimation (or plasma free nor metanephrine estimation), serum calcium and parathyroid hormone. (R) • Relevant imaging studies are advisable to guide the extent of surgery. (R) • RET (Proto-oncogene tyrosine-protein kinase receptor) proto-oncogene analysis should be performed after surgery. (R) • All patients with known or suspected MTC should have serum calcitonin and biochemical screening for phaeochromocytoma pre-operatively. (R) • All patients with proven MTC greater than 5 mm should undergo total thyroidectomy and central compartment neck dissection. (R) • Patients with MTC with lateral nodal involvement should undergo selective neck dissection (IIa-Vb). (R) • Patients with MTC with central node metastases should undergo ipsilateral prophylactic lateral node dissection. (R) • Prophylactic thyroidectomy should be offered to RET-positive family members. (R) • All patients with proven MTC should have genetic screening. (R) • Radiotherapy may be useful in controlling local symptoms in patients with inoperable disease. (R) • Chemotherapy with tyrosine kinase inhibitors may help in controlling local symptoms. (R) • For individuals with anaplastic thyroid carcinoma, initial assessment should focus on identifying the small proportion of patients with localised disease and good performance status, which may benefit from surgical resection and other adjuvant therapies. (G) • The surgical intent should be gross tumour resection and not merely an attempt at debulking. (G).

9 Guideline Pathological aspects of the assessment of head and neck cancers: United Kingdom National Multidisciplinary Guidelines. 2016

Helliwell, T R / Giles, T E. ·Department of Cellular Pathology,Liverpool Clinical Laboratories,University of Liverpool,UK. · Department of Cellular Pathology,Liverpool Clinical Laboratories,Liverpool,UK. ·J Laryngol Otol · Pubmed #27841114.

ABSTRACT: This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. It introduces the current best practice in histopathology and cytopathology as it pertains to head and neck and thyroid cancers. Recommendations • Accurate diagnosis of the type of malignancy is a key component of effective management. (R) • Surgeons and oncologists should understand the scope and limitations of cellular pathology in order to inform multidisciplinary discussions. (R) • A clinically suspected diagnosis of malignancy should be confirmed by biopsy or cytology before operation. (R) • Cytopathological diagnoses should be discussed with surgeons and radiologists to maximise the information gained from each modality of investigation. (R) • Pathological investigations are the basis for accurate cancer staging and stratification of clinical outcomes. (R).

10 Guideline Congenital hypothyroidism - Polish recommendations for therapy, treatment monitoring, and screening tests in special categories of neonates with increased risk of hypothyroidism. 2016

Kucharska, Anna Małgorzata / Beń-Skowronek, Iwona / Walczak, Mieczysław / Ołtarzewski, Mariusz / Szalecki, Mieczysław / Jackowska, Teresa / Lewiński, Andrzej / Bossowski, Artur. ·Department of Paediatrics and Endocrinology, Medical University of Warsaw, Poland. ankucharska@wum.edu.pl. ·Endokrynol Pol · Pubmed #27828692.

ABSTRACT: Proper treatment of congenital hypothyroidism warrants normal intellectual and physical development. This paper introduces the principles of treatment of congenital hypothyroidism, the recommended levothyroxine dosage, and the aims of therapy with its justification. The principles of treatment, specialist care of the patient, and methods used to evaluate therapeutic effects are described. Based on these data, recommendations concerning treatment and its monitoring in patients with congenital hypothyroidism are formulated. The paper also highlights the importance of educating the patients and/or their caretakers as one of the basic components of an effective therapy. The interpretation of screening tests in preterm neonates is provided as well. In the current screening program in preterm children TSH was determined between days three and five of life and then after three weeks. During this time TSH values are frequently low because of the immaturity of the hypothalamic-pituitary axis. Due to the increased risk of primary and secondary hypothyroidism in preterm and low birth weight babies the determination of TSH and fT4 between days three and five of life is recommended, irrespective of the screening test. (Endokrynol Pol 2016; 67 (5): 536-547).

11 Guideline 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). 2016

Satoh, Tetsurou / Isozaki, Osamu / Suzuki, Atsushi / Wakino, Shu / Iburi, Tadao / Tsuboi, Kumiko / Kanamoto, Naotetsu / Otani, Hajime / Furukawa, Yasushi / Teramukai, Satoshi / Akamizu, Takashi. ·Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan. ·Endocr J · Pubmed #27746415.

ABSTRACT: Thyroid storm is an endocrine emergency which is characterized by multiple organ failure due to severe thyrotoxicosis, often associated with triggering illnesses. Early suspicion, prompt diagnosis and intensive treatment will improve survival in thyroid storm patients. Because of its rarity and high mortality, prospective intervention studies for the treatment of thyroid storm are difficult to carry out. We, the Japan Thyroid Association and Japan Endocrine Society taskforce committee, previously developed new diagnostic criteria and conducted nationwide surveys for thyroid storm in Japan. Detailed analyses of clinical data from 356 patients revealed that the mortality in Japan was still high (∼11%) and that multiple organ failure and acute heart failure were common causes of death. In addition, multimodal treatment with antithyroid drugs, inorganic iodide, corticosteroids and beta-adrenergic antagonists has been suggested to improve mortality of these patients. Based on the evidence obtained by nationwide surveys and additional literature searches, we herein established clinical guidelines for the management of thyroid storm. The present guideline includes 15 recommendations for the treatment of thyrotoxicosis and organ failure in the central nervous system, cardiovascular system, and hepato-gastrointestinal tract, admission criteria for the intensive care unit, and prognostic evaluation. We also proposed preventive approaches to thyroid storm, roles of definitive therapy, and future prospective trial plans for the treatment of thyroid storm. We hope that this guideline will be useful for many physicians all over the world as well as in Japan in the management of thyroid storm and the improvement of its outcome.

12 Guideline Current recommendations in the management of hypothyroidism: developed from a statement by the British Thyroid Association Executive. 2016

Parretti, Helen / Okosieme, Onyebuchi / Vanderpump, Mark. ·Institute of Applied Health Research, University of Birmingham, Birmingham. · Consultant endocrinologist, Endocrine and Diabetes Department, Prince Charles Hospital, Merthyr Tydfil. · Consultant physician and endocrinologist, The Physicians' Clinic, London. ·Br J Gen Pract · Pubmed #27688516.

ABSTRACT: -- No abstract --

13 Guideline AIUM Practice Parameter for the Performance of a Thyroid and Parathyroid Ultrasound Examination. 2016

Anonymous390880. · ·J Ultrasound Med · Pubmed #27574124.

ABSTRACT: -- No abstract --

14 Guideline 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. 2016

Ross, Douglas S / Burch, Henry B / Cooper, David S / Greenlee, M Carol / Laurberg, Peter / Maia, Ana Luiza / Rivkees, Scott A / Samuels, Mary / Sosa, Julie Ann / Stan, Marius N / Walter, Martin A. ·1 Massachusetts General Hospital , Boston, Massachusetts. · 2 Endocrinology - Metabolic Service, Walter Reed National Military Medical Center , Bethesda, Maryland. · 3 Division of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins University School of Medicine , Baltimore, Maryland. · 4 Western Slope Endocrinology , Grand Junction, Colorado. · 5 Departments of Clinical Medicine and Endocrinology, Aalborg University and Aalborg University Hospital , Aalborg, Denmark . · 6 Thyroid Section, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul , Porto Alegre, Brazil . · 7 Pediatrics - Chairman's Office, University of Florida College of Medicine , Gainesville, Florida. · 8 Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University , Portland, Oregon. · 9 Section of Endocrine Surgery, Duke University School of Medicine , Durham, North Carolina. · 10 Division of Endocrinology, Mayo Clinic , Rochester, Minnesota. · 11 Institute of Nuclear Medicine, University Hospital Bern , Switzerland . ·Thyroid · Pubmed #27521067.

ABSTRACT: BACKGROUND: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspecialty physicians and others providing care for patients with this condition. METHODS: The American Thyroid Association (ATA) previously cosponsored guidelines for the management of thyrotoxicosis that were published in 2011. Considerable new literature has been published since then, and the ATA felt updated evidence-based guidelines were needed. The association assembled a task force of expert clinicians who authored this report. They examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to update the 2011 text and recommendations. The strength of the recommendations and the quality of evidence supporting them were rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group. RESULTS: Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' orbitopathy; and management of other miscellaneous causes of thyrotoxicosis. New paradigms since publication of the 2011 guidelines are presented for the evaluation of the etiology of thyrotoxicosis, the management of Graves' hyperthyroidism with antithyroid drugs, the management of pregnant hyperthyroid patients, and the preparation of patients for thyroid surgery. The sections on less common causes of thyrotoxicosis have been expanded. CONCLUSIONS: One hundred twenty-four evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal medical practice.

15 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE. 2016

Gharib, Hossein / Papini, Enrico / Garber, Jeffrey R / Duick, Daniel S / Harrell, R Mack / Hegedüs, Laszlo / Paschke, Ralf / Valcavi, Roberto / Vitti, Paolo / Anonymous8180867. · ·Endocr Pract · Pubmed #27167915.

ABSTRACT: Thyroid nodules are detected in up to 50 to 60% of healthy subjects. Most nodules do not cause clinically significant symptoms, and as a result, the main challenge in their management is to rule out malignancy, with ultrasonography (US) and fine-needle aspiration (FNA) biopsy serving as diagnostic cornerstones. The key issues discussed in these guidelines are as follows: (1) US-based categorization of the malignancy risk and indications for US-guided FNA (henceforth, FNA), (2) cytologic classification of FNA samples, (3) the roles of immunocytochemistry and molecular testing applied to thyroid FNA, (4) therapeutic options, and (5) follow-up strategy. Thyroid nodule management during pregnancy and in children are also addressed. On the basis of US features, thyroid nodules may be categorized into 3 groups: low-, intermediate-and high-malignancy risk. FNA should be considered for nodules ≤10 mm diameter only when suspicious US signs are present, while nodules ≤5 mm should be monitored rather than biopsied. A classification scheme of 5 categories (nondiagnostic, benign, indeterminate, suspicious for malignancy, or malignant) is recommended for the cytologic report. Indeterminate lesions are further subdivided into 2 subclasses to more accurately stratify the risk of malignancy. At present, no single cytochemical or genetic marker can definitely rule out malignancy in indeterminate nodules. Nevertheless, these tools should be considered together with clinical data, US signs, elastographic pattern, or results of other imaging techniques to improve the management of these lesions. Most thyroid nodules do not require any treatment, and levothyroxine (LT4) suppressive therapy is not recommended. Percutaneous ethanol injection (PEI) should be the first-line treatment option for relapsing, benign cystic lesions, while US-guided thermal ablation treatments may be considered for solid or mixed symptomatic benign thyroid nodules. Surgery remains the treatment of choice for malignant or suspicious nodules. The present document updates previous guidelines released in 2006 and 2010 by the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME).

16 Guideline 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism. 2016

Carney, Hazel C / Ward, Cynthia R / Bailey, Steven J / Bruyette, David / Dennis, Sonnya / Ferguson, Duncan / Hinc, Amy / Rucinsky, A Renee. ·WestVet Emergency and Specialty Center, 5019 North Sawyer Avenue, Garden City, ID 83617, USA Email: hcarney@westvet.net. · University of Georgia, College of Veterinary Medicine, 2200 College Station Road, Athens, GA 30605,USA Email: crward@uga.edu. · Exclusively Cats Veterinary Hospital, 6650 Highland Road, Ste 116, Waterford, MI 48327, USA. · VCA West Los Angeles Animal Hospital, 1900 South Sepulveda Blvd, Los Angeles, CA 90025, USA. · Stratham-Newfields Veterinary Hospital, 8 Main Street, Newfields, NH 03856, USA. · College of Veterinary Medicine - University of Illinois, Department of Comparative Biosciences, 3840 Veterinary Medicine Basic Sciences Bldg, 2001 South Lincoln Avenue, Urbana, IL 61802, USA. · Cosmic Cat Veterinary Clinic, 220 East Main Street, Branford, CT 06405, USA. · Mid Atlantic Cat Hospital, 201 Grange Hall Road, Queenstown, MD 21658, USA. ·J Feline Med Surg · Pubmed #27143042.

ABSTRACT: CLINICAL CONTEXT: Since 1979 and 1980 when the first reports of clinical feline hyperthyroidism (FHT) appeared in the literature, our understanding of the disease has evolved tremendously. Initially, FHT was a disease that only referral clinicians treated. Now it is a disease that primary clinicians routinely manage. Inclusion of the measurement of total thyroxine concentration in senior wellness panels, as well as in diagnostic work-ups for sick cats, now enables diagnosis of the condition long before the cat becomes the classic scrawny, unkempt, agitated patient with a bulge in its neck. However, earlier recognition of the problem has given rise to several related questions: how to recognize the health significance of the early presentations of the disease; how early to treat the disease; whether to treat FHT when comorbid conditions are present; and how to manage comorbid conditions such as chronic kidney disease and cardiac disease with treatment of FHT. The 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism (hereafter referred to as the Guidelines) will shed light on these questions for the general practitioner and suggest when referral may benefit the cat. SCOPE: The Guidelines explain FHT as a primary disease process with compounding factors, and provide a concise explanation of what we know to be true about the etiology and pathogenesis of the disease.The Guidelines also:Distill the current research literature into simple recommendations for testing sequences that will avoid misdiagnosis and separate an FHT diagnosis into six clinical categories with associated management strategies.Emphasize the importance of treating all hyperthyroid cats, regardless of comorbidities, and outline the currently available treatments for the disease.Explain how to monitor the treated cat to help avoid exacerbating comorbid diseases.Dispel some of the myths surrounding certain aspects of FHT and replace them with an evidence-based narrative that veterinarians and their practice teams can apply to feline patients and communicate to their owners. EVIDENCE BASE: To help ensure better case outcomes, the Guidelines reflect currently available, evidenced-based knowledge. If research is lacking, or if a consensus does not exist, the expert panel of authors has made recommendations based on their extensive, cumulative clinical experience.

17 Guideline American Cancer Society Head and Neck Cancer Survivorship Care Guideline. 2016

Cohen, Ezra E W / LaMonte, Samuel J / Erb, Nicole L / Beckman, Kerry L / Sadeghi, Nader / Hutcheson, Katherine A / Stubblefield, Michael D / Abbott, Dennis M / Fisher, Penelope S / Stein, Kevin D / Lyman, Gary H / Pratt-Chapman, Mandi L. ·Medical Oncologist, Moores Cancer Center, University of California at San Diego, La Jolla, CA. · Retired Head and Neck Surgeon, Former Associate Professor of Otolaryngology and Head and Neck Surgery, Louisiana State University Health and Science Center, New Orleans, LA. · Program Manager, National Cancer Survivorship Resource Center, American Cancer Society, Atlanta, GA. · Research Analyst-Survivorship, American Cancer Society, Atlanta, GA. · Professor of Surgery, Division of Otolaryngology-Head and Neck Cancer Surgery, and Director of Head and Neck Surgical Oncology, George Washington University, Washington, DC. · Associate Professor, Department of Head and Neck Surgery, Section of Speech Pathology and Audiology, The University of Texas MD Anderson Cancer Center, Houston, TX. · Medical Director for Cancer Rehabilitation, Kessler Institute for Rehabilitation, West Orange, NJ. · Chief Executive Officer, Dental Oncology Professionals, Garland, TX. · Clinical Instructor of Otolaryngology and Nurse, Miller School of Medicine, Department of Otolaryngology, Division of Head and Neck Surgery, University of Miami, Miami, FL. · Vice President, Behavioral Research, and Director, Behavioral Research Center, American Cancer Society, Atlanta, GA. · Co-Director, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, and Professor of Medicine, University of Washington School of Medicine, Seattle, WA. · Director, The George Washington University Cancer Institute, Washington, DC. ·CA Cancer J Clin · Pubmed #27002678.

ABSTRACT: Answer questions and earn CME/CNE The American Cancer Society Head and Neck Cancer Survivorship Care Guideline was developed to assist primary care clinicians and other health practitioners with the care of head and neck cancer survivors, including monitoring for recurrence, screening for second primary cancers, assessment and management of long-term and late effects, health promotion, and care coordination. A systematic review of the literature was conducted using PubMed through April 2015, and a multidisciplinary expert workgroup with expertise in primary care, dentistry, surgical oncology, medical oncology, radiation oncology, clinical psychology, speech-language pathology, physical medicine and rehabilitation, the patient perspective, and nursing was assembled. While the guideline is based on a systematic review of the current literature, most evidence is not sufficient to warrant a strong recommendation. Therefore, recommendations should be viewed as consensus-based management strategies for assisting patients with physical and psychosocial effects of head and neck cancer and its treatment. CA Cancer J Clin 2016;66:203-239. © 2016 American Cancer Society.

18 Guideline Laryngeal examination in thyroid and parathyroid surgery: An American Head and Neck Society consensus statement: AHNS Consensus Statement. 2016

Sinclair, Catherine F / Bumpous, Jeffrey M / Haugen, Bryan R / Chala, Andres / Meltzer, Daniel / Miller, Barbra S / Tolley, Neil S / Shin, Jennifer J / Woodson, Gayle / Randolph, Gregory W. ·Department of Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY. · Department of Otolaryngology, University of Louisville, Louisville, Kentucky. · University of Colorado School of Medicine, Aurora, CO. · University of Caldas, Manizales, Caldas, Colombia, South America. · Mount Sinai, New York, New York. · Department of Surgery, University of Michigan, Ann Arbor, Michigan. · Department of Surgery, Imperial College of London, London, United Kingdom. · Harvard, Boston, Massachusetts. · Department of Otolaryngology, Southern Illinois University School of Medicine, Carbondale, Illinois. · Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. ·Head Neck · Pubmed #26970554.

ABSTRACT: This American Head and Neck Society (AHNS) consensus statement discusses the techniques of laryngeal examination for patients undergoing thyroidectomy and parathyroidectomy. It is intended to help guide all clinicians who diagnose or manage adult patients with thyroid disease for whom surgery is indicated, contemplated, or has been performed. This consensus statement concludes that flexible transnasal laryngoscopy is the optimal laryngeal examination technique, with other techniques including laryngeal ultrasound and stroboscopy being useful in selected scenarios. © 2016 Wiley Periodicals, Inc. Head Neck 38: 811-819, 2016.

19 Guideline Diagnostics and Treatment of Thyroid Carcinoma. 2016

Jarząb, Barbara / Dedecjus, Marek / Handkiewicz-Junak, Daria / Lange, Dariusz / Lewiński, Andrzej / Nasierowska-Guttmejer, Anna / Ruchała, Marek / Słowińska-Klencka, Dorota / Nauman, Janusz / Adamczewski, Zbigniew / Bagłaj, Maciej / Bałdys-Waligórska, Agata / Barczyński, Marcin / Bednarczuk, Tomasz / Cichocki, Andrzej / Czarniecka, Agnieszka / Czepczyński, Rafał / Gawlik, Aneta / Hubalewska-Dydejczyk, Alicja / Jażdżewski, Krystian / Kamiński, Grzegorz / Karbownik-Lewińska, Małgorzata / Kos-Kudła, Beata / Kułakowski, Andrzej / Kuzdak, Krzysztof / Łącka, Katarzyna / Małecka-Tendera, Ewa / Niedziela, Marek / Pomorski, Lech / Sporny, Stanisław / Stojcev, Zoran / Syrenicz, Anhelli / Włoch, Jan / Krajewska, Jolanta / Szpak-Ulczok, Sylwia / Kalemba, Michal / Buziak-Bereza, Monika. ·Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice. bjarzab@io.gliwice.pl. ·Endokrynol Pol · Pubmed #26884119.

ABSTRACT: Revised Guidelines of Polish National Societies Prepared on the initiative of the Polish Group for Endocrine Tumours approved in their final version between November 16th and 28th, 2015 by the Scientific Committee of the V Conference "Thyroid Cancer and other malignancies of endocrine glands" organised between November 14th and 17th, 2015 in Wisla, Poland; called by the following Societies: Polish Endocrine Society, Polish Society of Oncology, Polish Thyroid Association, Polish Society of Pathologists, Society of Polish Surgeons, Polish Society of Surgical Oncology, Polish Society of Clinical Oncology, Polish Society of Radiation Oncology, Polish Society of Nuclear Medicine, Polish Society of Paediatric Endocrinology, Polish Society of Paediatric Surgeons, Polish Society of Ultrasonography Gliwice-Wisła, 2015 DECLARATION: These recommendations are created by the group of delegates of the National Societies, which declare their willingness to participate in the preparation of the revised version of the Polish Guidelines. The members of the Working Group have been chosen from the specialists involved in medical care of patients with thyroid carcinoma. Directly before the preparation of the Polish national recommendations the American Thyroid Association (ATA) published its own guidelines together with a wide comment fulfilling evidence-based medicine (EBM) criteria. ATA Guidelines are consistent with National Comprehensive Cancer Network (NCCN) Recommendation. According to the members of the Working Group, it is necessary to adapt them to both the specific Polish epidemiological situation as well as to the rules referring to the Polish health system. Therefore, the Polish recommendations constitute a consensus of the experts' group, based on ATA information. The experts analysed previous Polish Guidelines, published in 2010, and other available data, and after discussion summed up the results in the form of these guidelines. It should be added that Part II, which constitutes a pathological part, has been available at the website of the Polish Society of Pathologists for acceptance of the members of the Society, and no essential comments have been proposed. The Members of the Group decided that a subgroup elected from among them would update the Guidelines, according to EBM rules, every year. The Revised Guidelines should help physicians to make reasonable choices in their daily practice; however, the final decision concerning an individual patient should be made by the caring physician responsible for treatment, or optimally by a therapeutic tumour board together with the patient, and should take into consideration the patient's health condition. It should be emphasised that the recommendations may not constitute a strict standard of clinical management imposed on medical staff. The data from clinical trials concerning numerous clinical situations are scarce. In such moments the opinion of the management may differ from the recommendations after considering possible benefits and disadvantages for the patient.

20 Guideline American Thyroid Association Statement on Remote-Access Thyroid Surgery. 2016

Berber, Eren / Bernet, Victor / Fahey, Thomas J / Kebebew, Electron / Shaha, Ashok / Stack, Brendan C / Stang, Michael / Steward, David L / Terris, David J / Anonymous280858. ·1 Department of Endocrine Surgery, Cleveland Clinic , Cleveland, Ohio. · 2 Division of Endocrinology, Mayo Clinic , Jacksonville, Florida. · 3 Department of Endocrine Surgery, Weill Cornell Medical College/New York Presbyterian Hospital , New York, New York. · 4 Endocrine Oncology Branch, National Cancer Institutes of Health , Bethesda, Maryland. · 5 Department of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center , New York, New York. · 6 Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences , Little Rock, Arkansas. · 7 Division of Endocrine Surgery, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania. · 8 Department of Otolaryngology-Head and Neck Surgery, University Hospital , Cincinnati, Ohio. · 9 Department of Otolaryngology, Augusta University , Augusta, Georgia . ·Thyroid · Pubmed #26858014.

ABSTRACT: BACKGROUND: Remote-access techniques have been described over the recent years as a method of removing the thyroid gland without an incision in the neck. However, there is confusion related to the number of techniques available and the ideal patient selection criteria for a given technique. The aims of this review were to develop a simple classification of these approaches, describe the optimal patient selection criteria, evaluate the outcomes objectively, and define the barriers to adoption. METHODS: A review of the literature was performed to identify the described techniques. A simple classification was developed. Technical details, outcomes, and the learning curve were described. Expert opinion consensus was formulated regarding recommendations for patient selection and performance of remote-access thyroid surgery. RESULTS: Remote-access thyroid procedures can be categorized into endoscopic or robotic breast, bilateral axillo-breast, axillary, and facelift approaches. The experience in the United States involves the latter two techniques. The limited data in the literature suggest long operative times, a steep learning curve, and higher costs with remote-access thyroid surgery compared with conventional thyroidectomy. Nevertheless, a consensus was reached that, in appropriate hands, it can be a viable option for patients with unilateral small nodules who wish to avoid a neck incision. CONCLUSIONS: Remote-access thyroidectomy has a role in a small group of patients who fit strict selection criteria. These approaches require an additional level of expertise, and therefore should be done by surgeons performing a high volume of thyroid and robotic surgery.

21 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THYROID DYSFUNCTION CASE FINDING. 2016

Hennessey, James V / Garber, Jeffrey R / Woeber, Kenneth A / Cobin, Rhoda / Klein, Irwin / Anonymous4760857 / Anonymous4770857. · ·Endocr Pract · Pubmed #26848631.

ABSTRACT: Hypothyroidism and hyperthyroidism can be readily diagnosed and can be treated in a safe, cost-effective manner. Professional organizations have given guidance on how and when to employ thyroid-stimulating hormone testing for the detection of thyroid dysfunction. Most recently, the United States Preventive Services Task Force did not endorse screening for thyroid dysfunction based on a lack of proven benefit and potential harm of treating those with thyroid dysfunction, which is mostly subclinical disease. The American Association of Clinical Endocrinologists (AACE) is concerned that this may discourage physicians from testing for thyroid dysfunction when clinically appropriate. Given the lack of specificity of thyroid-associated symptoms, the appropriate diagnosis of thyroid disease requires biochemical confirmation. The Thyroid Scientific Committee of the AACE has produced this White Paper to highlight the important difference between screening and case-based testing in the practice of clinical medicine. We recommend that thyroid dysfunction should be frequently considered as a potential etiology for many of the nonspecific complaints that physicians face daily. The application and success of safe and effective interventions are dependent on an accurate diagnosis. We, therefore, advocate for an aggressive case-finding approach, based on identifying those persons most likely to have thyroid disease that will benefit from its treatment.

22 Guideline External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. 2016

Kiess, Ana P / Agrawal, Nishant / Brierley, James D / Duvvuri, Umamaheswar / Ferris, Robert L / Genden, Eric / Wong, Richard J / Tuttle, R Michael / Lee, Nancy Y / Randolph, Gregory W. ·Department of Radiation Oncology, Johns Hopkins Medical Institute, Baltimore, Maryland. · Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins Medical Institute, Baltimore, Maryland. · Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. · Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. · VA Pittsburgh Health System, Pittsburgh, Pennsylvania. · Department of Otolaryngology, Mount Sinai Hospital, New York, New York. · Department of Surgery - Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Medicine - Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts. ·Head Neck · Pubmed #26716601.

ABSTRACT: The use of external-beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) is debated because of a lack of prospective clinical data, but recent retrospective studies have reported benefits in selected patients. The Endocrine Surgery Committee of the American Head and Neck Society provides 4 recommendations regarding EBRT for locoregional control in DTC, based on review of literature and expert opinion of the authors. (1) EBRT is recommended for patients with gross residual or unresectable locoregional disease, except for patients <45 years old with limited gross disease that is radioactive iodine (RAI)-avid. (2) EBRT should not be routinely used as adjuvant therapy after complete resection of gross disease. (3) After complete resection, EBRT may be considered in select patients >45 years old with high likelihood of microscopic residual disease and low likelihood of responding to RAI. (4) Cervical lymph node involvement alone should not be an indication for adjuvant EBRT.

23 Guideline Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). 2016

Grande, E / Santamaría Sandi, J / Capdevila, J / Navarro González, E / Zafón Llopis, C / Ramón Y Cajal Asensio, T / Gómez Sáez, J M / Jiménez-Fonseca, P / Riesco-Eizaguirre, G / Galofré, J C. ·Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar km 9,1, 28034, Madrid, Spain. egrande@oncologiahrc.com. · Endocrinology and Nutrition Service, Hospital Universitario de Cruces, Vizcaya, Spain. · Medical Oncology Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain. · Endocrinology and Nutrition Service, Hospital Universitario Virgen del Rocio, Seville, Spain. · Endocrinology and Nutrition Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain. · Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. · CIBERDEM, Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, Barcelona, Spain. · Medical Oncology Service, Hospital Universitario Central de Asturias, Oviedo, Spain. · Endocrinology and Nutrition Service, Hospital Universitario de Móstoles, Madrid, Spain. · Endocrinology and Nutrition Service, Clínica Universidad de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #26687366.

ABSTRACT: BACKGROUND: Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny. METHODS: The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed. RESULTS: This consensus updates and summarizes biology, treatment and prognostic considerations of MTC. CONCLUSIONS: Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12-14 months. Wait and see strategy should be offered to patients with: disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression.

24 Guideline Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. 2016

Riesco-Eizaguirre, Garcilaso / Galofré, Juan Carlos / Grande, Enrique / Zafón Llopis, Carles / Ramón y Cajal Asensio, Teresa / Navarro González, Elena / Jiménez-Fonseca, Paula / Santamaría Sandi, Javier / Gómez Sáez, José Manuel / Capdevila, Jaume. ·Department of Endocrinology and Nutrition, Hospital Universitario de Móstoles, Madrid, Spain. Electronic address: griesco@iib.uam.es. · Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Navarra, Spain. · Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain. · Department of Endocrinology and Nutrition, Vall d'Hebron University Hospital, Barcelona, Spain. · Medical Oncology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain. · Department of Endocrinology and Nutrition, Vírgen del Rocío University Hospital, Sevilla, Spain. · Medical Oncology Department, Central de Asturias University Hospital, Oviedo, Asturias, Spain. · Department of Endocrinology and Nutrition, Hospital Universitario de Cruces, Baracaldo, Vizcaya, Spain. · CIBERDEM Service of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Barcelona, Spain. · Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. ·Endocrinol Nutr · Pubmed #26601805.

ABSTRACT: BACKGROUND: Approximately one third of the patients with differentiated thyroid cancer (DTC) who develop structurally-evident metastatic disease are refractory to radioactive iodine (RAI). Most deaths from thyroid cancer occur in these patients. The main objective of this consensus is to address the most controversial aspects of management of these patients. METHODS: On behalf of the Spanish Society of Endocrinology & Nutrition (SEEN) and the Spanish Group for Orphan and Infrequent Tumors (GETHI), the Spanish Task Force for Thyroid Cancer, consisting of endocrinologists and oncologists, reviewed the relevant literature and prepared a series of clinically relevant questions related to management of advanced RAI-refractory DTC. RESULTS: Ten clinically relevant questions were identified by the task force. In answering to these 10 questions, the task force included recommendations regarding the best definition of refractoriness; the best therapeutic options including watchful waiting, local therapies, and systemic therapy (e.g. kinase inhibitors), when sodium iodide symporter (NIS) restoration may be expected; and how recent advances in molecular biology have increased our understanding of the disease. CONCLUSIONS: In response to our appointment as a task force by the SEEN and GHETI, we developed a consensus to help in clinical management of patients with advanced RAI-refractory DTC. We think that this consensus will provide helpful and current recommendations that will help patients with this disorder to get optimal medical care.

25 Guideline 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2016

Haugen, Bryan R / Alexander, Erik K / Bible, Keith C / Doherty, Gerard M / Mandel, Susan J / Nikiforov, Yuri E / Pacini, Furio / Randolph, Gregory W / Sawka, Anna M / Schlumberger, Martin / Schuff, Kathryn G / Sherman, Steven I / Sosa, Julie Ann / Steward, David L / Tuttle, R Michael / Wartofsky, Leonard. ·1 University of Colorado School of Medicine , Aurora, Colorado. · 2 Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts. · 3 The Mayo Clinic , Rochester, Minnesota. · 4 Boston Medical Center , Boston, Massachusetts. · 5 Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania. · 6 University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania. · 7 The University of Siena , Siena, Italy . · 8 Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital , Harvard Medical School, Boston, Massachusetts. · 9 University Health Network, University of Toronto , Toronto, Ontario, Canada . · 10 Institute Gustave Roussy and University Paris Sud , Villejuif, France . · 11 Oregon Health and Science University , Portland, Oregon. · 12 University of Texas M.D. Anderson Cancer Center , Houston, Texas. · 13 Duke University School of Medicine , Durham, North Carolina. · 14 University of Cincinnati Medical Center , Cincinnati, Ohio. · 15 Memorial Sloan Kettering Cancer Center , New York, New York. · 16 MedStar Washington Hospital Center , Washington, DC. ·Thyroid · Pubmed #26462967.

ABSTRACT: BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. METHODS: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. RESULTS: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. CONCLUSIONS: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.

Next